Edition:
India

Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

6.10EUR
9:05pm IST
Change (% chg)

€-0.15 (-2.40%)
Prev Close
€6.25
Open
€6.24
Day's High
€6.24
Day's Low
€6.10
Volume
22,143
Avg. Vol
28,595
52-wk High
€9.86
52-wk Low
€5.61

Latest Key Developments (Source: Significant Developments)

Erytech Proposes Appointment Of Dr. Jean-Paul Kress As Chairman Of The Board Of Directors
Monday, 6 May 2019 

May 6 (Reuters) - ERYTECH PHARMA SA ::ERYTECH PROPOSES THE APPOINTMENT OF DR. JEAN-PAUL KRESS AS CHAIRMAN OF THE BOARD OF DIRECTORS.  Full Article

Erytech Pharma FY Total Operating Loss Widens To 43.6 Million Euros
Tuesday, 12 Mar 2019 

March 12(Reuters) - ERYTECH PHARMA SA ::ANNOUNCED ON MONDAY, ERYTECH PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR FULL YEAR 2018.CASH POSITION OF EUR 134.4 MILLION ($153.9 MILLION) AT YEAR-END.FY TOTAL OPERATING INCOME EUR 4.4 MLN VS EUR 3.4 MLN YEAR AGO.FY NET LOSS OF EUR 38.2 MLN VS LOSS OF EUR 33.5 MLN YEAR AGO.FY TOTAL OPERATING LOSS OF EUR 43.6 MLN VS LOSS OF EUR 30.9 MLN YEAR AGO.EXPECTED OVER NEXT 12 MONTHS:FIRST PATIENT ENROLLED IN TRYBECA-2, PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL IN TNBC.EXPECTED OVER NEXT 12 MONTHS:START OF GMP PRODUCTION AT PRINCETON FACILITY AND LYON EXTENSION.EXPECTED OVER NEXT 12 MONTHS:START OF US PATIENT ENROLMENT IN TRYBECA 1, PHASE 3 TRIAL IN SECOND-LINE PANCREATIC CANCER.EXPECTED OVER NEXT 12 MONTHS:INITIATION OF PHASE 1 CLINICAL TRIAL WITH ERYMETHIONASE.  Full Article

Erytech Presents Findings At European Red Cell Research Society Meeting
Monday, 11 Mar 2019 

March 11 (Reuters) - ERYTECH PHARMA SA ::ERYTECH PRESENTS FINDINGS AT EUROPEAN RED CELL RESEARCH SOCIETY MEETING.IN AN EARLIER 141 PATIENT RANDOMIZED PHASE 2B TRIAL OF ERYASPASE IN COMBINATION WITH CHEMOTHERAPY FOR TREATMENT OF SECOND-LINE METASTATIC PANCREATIC CANCER, SIGNIFICANT IMPROVEMENTS IN OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL WERE OBSERVED VERSUS CHEMOTHERAPY ALONE WITH NO APPARENT INCREASE IN TOXICITY.WITH EXCEPTION OF L-ASPARAGINASE, ANALYSIS REVEALED NO SIGNIFICANT DIFFERENCE IN PROTEOMIC LANDSCAPE WHEN COMPARING PACKED RBCS, ERYCAPS®-PROCESSED RBCS WITHOUT ENZYME, AND ERYCAPS®-PROCESSED RBCS ENCAPSULATING L-ASPARAGINASE.RESULTS CONFIRM THAT ERYCAPS® PROCESS DOES NOT SIGNIFICANTLY ALTER PROPERTIES OF RBCS.RESULTS CONFIRM THAT APART FROM ENCAPSULATED DRUG SUBSTANCE, RBC-BASED THERAPEUTICS PRODUCED USING THIS PROCESS HAVE SIMILAR CHARACTERISTICS TO THAT OF UNPROCESSED PACKED RBCS.  Full Article

Erytech Pharma 9-Month Operating Loss Widens To 34.1 Million Euros
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - ERYTECH PHARMA SA ::ANNOUNCED ON MONDAY CASH POSITION OF EUR 146.9 MLN AS OF SEPT 30, 2018, COMPARED WITH EUR 185.5 MLN AS OF DEC 31, 2017.9-MONTH NET LOSS EUR 30.2 MLN, COMPARED TO LOSS OF EUR 20.8 MLN IN THE SAME PERIOD OF 2017.9-MONTH OPERATING LOSS EUR 34.1 MLN VS LOSS OF EUR 21.1 MLN YEAR AGO.9-MONTH TOTAL OPERATING INCOME EUR 2.6 MLN VS EUR 2.9 MLN YEAR AGO.PHASE 2 TRIAL IN TRIPLE-NEGATIVE BREAST CANCER TO ENROLL PATIENTS BY YEAR END.PHASE 3 TRIAL FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER ENROLLING PATIENTS.  Full Article

Erytech Pharma Q1 Net Loss Widens To 11.7 Million Euros
Tuesday, 15 May 2018 

May 14 (Reuters) - ERYTECH PHARMA SA ::CASH POSITION OF €171.8 MILLION ($211.6 MILLION) AS OF MARCH 31, 2018.FINALIZED PHASE 3 TRIAL DESIGN FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER; ON TRACK FOR EXPECTED START OF PATIENT ENROLLMENT IN Q3.SELECTED TRIPLE-NEGATIVE BREAST CANCER AS THE NEXT SOLID TUMOR INDICATION; PREPARING PHASE 2 TRIAL WITH EXPECTED START OF PATIENT ENROLLMENT IN Q3.REPORTED POSITIVE U.S. PHASE 1 TRIAL RESULTS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA; DISCUSSION WITH FDA UPCOMING.Q1 NET LOSS EUR 11.7 MILLION VERSUS LOSS OF EUR 6.5 MILLION YEAR AGO.  Full Article

Erytech Appoints Alex Dusek As VP Of Commercial Strategy
Monday, 14 May 2018 

May 14 (Reuters) - ERYTECH PHARMA SA ::ERYTECH STRENGTHENS EXECUTIVE TEAM WITH THE APPOINTMENT OF ALEX DUSEK AS VP OF COMMERCIAL STRATEGY.  Full Article

Erytech Reports Results Of Phase 2b Study Of Eryaspase For The Treatment Of AML
Friday, 8 Dec 2017 

Dec 8 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS TOP-LINE RESULTS OF PHASE 2B STUDY OF ERYASPASE FOR THE TREATMENT OF AML.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS).OS HAZARD RATIO (HR) WAS 1.06 (95% CI; 0.70, 1.61).WHEN ADJUSTING FOR MINOR IMBALANCES IN MAIN PROGNOSTIC FACTORS AT BASELINE OS HR WAS 0.98 (95% CI; 0.64, 1.50).MEDIAN NUMBER OF MONTHS ON TREATMENT WAS LESS THEN 2 MONTHS IN BOTH TREATMENT ARMS.  Full Article

Erytech Pharma SA ADS debut about 14.7 pct above IPO price
Friday, 10 Nov 2017 

Nov 10 (Reuters) - :Erytech Pharma SA ADS open at $26.68 in debut on the NASDAQ versus IPO price of $23.26 per ADS‍​‍​​.  Full Article

Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​.‍GLOBAL OFFERING COMPRISING AN OFFER OF 4.7 MILLION ORDINARY SHARES IN FORM OF AMERICAN DEPOSITARY SHARES​.IN ‍UNITED STATES, OFFERING PRICE OF $23.26 PER ADS​.‍PRIVATE PLACEMENT IN EUROPE (INCL. FRANCE) AND OTHER COUNTRIES (EXCLUDING. US AND CANADA) OF 0.7 MILLION ORDINARY SHARES AT OFFERING PRICE OF EUR 20 PER SHARE.‍LISTING ON NASDAQ GLOBAL SELECT MARKET UNDER TICKER SYMBOL "ERYP"​.‍GLOBAL OFFERING FOR TOTAL GROSS PROCEEDS OF ABOUT $125 MILLION BEFORE DEDUCTING UNDERWRITING COMMISSIONS AND ESTIMATED EXPENSES PAYABLE BY CO​.‍CLOSING OF GLOBAL OFFERING EXPECTED ON OR ABOUT NOV 14, 2017​.‍FOLLOWING CLOSING COMPANY WILL HAVE ISSUED 5,374,033 ORDINARY SHARES (INCL. ADSS)​.  Full Article

Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - ERYTECH PHARMA SA ::ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS.SUSPENSION TO ALLOW FOR CONFIRMATION OF ALLOCATIONS TO INVESTORS & CO'S ADSS BEGINNING TRADING ON NASDAQ GLOBAL SELECT MARKET .‍SUSPENSION EFFECTIVE UNTIL A NEW COMMUNICATION IS RELEASED BY COMPANY​.‍TRADING ON REGULATED MARKET OF EURONEXT PARIS EXPECTED TO RESUME NOV 10, 2017 ABOUT 4:00 PM (CET)​.  Full Article

BRIEF-Erytech Announces Immune Modulation Strategic Collaboration With SQZ Biotechnologies

* ERYTECH ANNOUNCED ON MONDAY IT HAS ENTERED INTO AN AGREEMENT WITH SQZ BIOTECHNOLOGIES TO ADVANCE NOVEL RBC-BASED THERAPEUTICS FOR IMMUNE MODULATION